Empowered Funds LLC Takes $3.29 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Empowered Funds LLC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 218,336 shares of the company's stock, valued at approximately $3,286,000. Empowered Funds LLC owned approximately 0.47% of Pacira BioSciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PCRX. SG Americas Securities LLC bought a new position in Pacira BioSciences during the 1st quarter valued at $106,000. ProShare Advisors LLC boosted its stake in Pacira BioSciences by 8.0% during the first quarter. ProShare Advisors LLC now owns 12,461 shares of the company's stock valued at $364,000 after buying an additional 924 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Pacira BioSciences by 18.5% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,412 shares of the company's stock worth $450,000 after acquiring an additional 2,410 shares during the period. Vanguard Group Inc. raised its position in Pacira BioSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock worth $149,413,000 after acquiring an additional 14,960 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in Pacira BioSciences by 2.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock valued at $34,250,000 after acquiring an additional 26,463 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Up 0.5 %

NASDAQ:PCRX traded up $0.09 on Tuesday, hitting $16.73. 917,944 shares of the company's stock traded hands, compared to its average volume of 856,341. The firm has a 50-day moving average price of $15.87 and a 200-day moving average price of $20.52. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market cap of $772.42 million, a PE ratio of -8.22 and a beta of 0.82. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.95.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $10.00 target price (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. HC Wainwright reduced their price objective on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Piper Sandler lowered Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Finally, Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Pacira BioSciences currently has a consensus rating of "Hold" and an average target price of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.